Abstract 47P
Background
Studies have shown disparities in management of older patients with breast cancer, resulting in undertreatment. Older patients with co-morbidities pose a challenge for cancer care providers who must balance the risk of death due to toxicity from treatment versus the benefit of standard multimodality treatment. The aim of the study was to evaluate whether the sequencing of chemotherapy and surgery impact the ability to deliver both modalities of treatment.
Methods
A retrospective analysis of prospective data was evaluated between 2018 and 2022. We included patients >60 years of age with chronic comorbidities, with a clinical stage T1c-3 and N0-3, HER2-positive or triple-negative invasive breast cancer treated with chemotherapy alone, surgery alone, or both surgery and chemotherapy. Kaplan-Meier curves were plotted to compare the survival outcomes. Statistical analysis was done using SPSS v25.
Results
A total of 821 patients met the inclusion criteria, of whom 85.9% (N=705) underwent surgery as the initial treatment. Among patients who received chemotherapy first (N=116), 73.3% (N=85) were able to complete subsequent surgery. Factors associated with completion surgery after chemotherapy were younger age and clinical node-negative status. Among patients treated with surgery first, only 36.3% (N=256) received adjuvant chemotherapy. Among patients who received both modalities of treatment (N=341), women with more advanced stage tumors and those diagnosed in recent years were more likely to receive neoadjuvant chemotherapy. With a median follow-up of 19.3 months, cN0 patients who underwent both surgery and chemotherapy had significantly better overall survival compared to patients who received single modality of treatment.
Conclusions
In older, triple-negative or HER2-positive breast cancer patients with comorbidities, receipt of chemotherapy and surgery was associated with improved survival. Neoadjuvant chemotherapy group were twice as likely to receive both modalities of treatment than those undergoing surgery first. A multidisciplinary approach to evaluate geriatric patients with comorbidities is essential to deliver appropriate treatment and improve outcomes in this vulnerable population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract